
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is well-positioned for growth in the transplant market, with a strong focus on precision medicine and a diversified portfolio of testing services. While there may be potential challenges in commercializing new products, the company's solid financial performance and strategic investments bode well for long-term success. With a promising new product on the horizon and a commitment to reaching their financial targets, CareDx appears to be a strong investment opportunity in the healthcare sector.
Bears say
CareDx is a precision medicine company focused on the discovery, development, and commercialization of high-value healthcare solutions for transplant patients. The company's recent earnings call and investor meeting schedule forecasted strong financial targets for 2026 and 2027, including a 15% revenue CAGR, >70% gross margin target, and 20% Adj. EBITDA margin target. However, we have concerns about its reliance on acquisitions for growth, potential regulatory challenges, and competition from Natera in the transplant market.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares